GuangXi Center for Diseases Control and Prevention
Nanning, Guangxi, China
NCT Number: NCT01421121
A randomized, placebo-controlled, double-blind clinical trial is to evaluate the safety and immunogenicity of a new inactivated EV71 vaccine developed by Sinovac Biotech CO., LTD.
Looking for future studies?
Notify Me6 month–35 month
All sexes
Interventional
Phase 2
Nanning, Guangxi, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
Other names: EV71 vaccine
inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
Other names: EV71 vaccine
inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
Other names: EV71 vaccine
inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
Other names: EV71 vaccine
0.5ml placebo, two doses, 28 days interval
Time frame: 6 month
Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus >= 1:8
Time frame: 6 months
solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site.
solicited general adverse events include Fever, Nausea, Vomiting, Diareahhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy
Sinovac Biotech Co., Ltd
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial DetailsNCT01273246
Coxsackievirus Infections, Enterovirus Infections
Nanning, Guangxi, China
View Trial DetailsNCT01273233
Enterovirus Infections, Infection; Viral, Enterovirus
Nanning, Guangxi, China
View Trial DetailsNCT07552779
COVID-19, COVID-19 (Coronavirus Disease 2019)
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial Details